Interleukin response in cardiovascular diseases: an overview

Mariya Negreva; Svetoslav Georgiev; Katerina Vitlianova

doi:10.14748/ssm.v47i2.1242

Interleukin response in cardiovascular diseases: an overview

Mariya Negreva, Svetoslav Georgiev, Katerina Vitlianova

Abstract

Interleukins are important modulators of the immune response in the human body, which inevitably makes them participants in the intimate mechanisms of various diseases. Cardiovascular morbidity and mortality is high in the world as a whole, despite the ongoing primary and secondary prevention. Therefore their pathogenetic mechanisms are of significant research and clinical interest. A number of studies demonstrated changes in the interleukin status of patients with coronary heart disease, heart failure, some cardiomyopathies and rhythm conduction disorders. Significantly altered levels of basic for the immunity pro-inflammatory and anti-inflammatory cytokines were found. It was even proven, that some of them have predictive value for the manifestation of certain diseases. All this is a reason to allow interleukins to take part in the intimate mechanisms of cardiovascular diseases and consider the place of interleukin blockers in the treatment of these diseases.

Keywords

interleukins; inflammation; cardiovascular diseases

Full Text

References

Aarden LA, Brunner TK, Cerottini JC, Dayer JM et al. Revised nomenclature for antigen-non-specific T cell proliferation and helper factors. J. Immunol. 1979 Dec;123(6):2928-9.

Khan MM, Immunopharmacology. Springer US; 2008.

Commins SP, Borish L, Steinke JW. Immunologic messenger molecules: cytokines, interferons, and chemokines. J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S53-72.

Brocker C, Thompson D, Matsumoto A, Nebert DW, Vasiliou V. Evolutionary divergence and functions of the human interleukin (IL) gene family. Hum Genomics. 2010;5(1):30-55.

AK Shrivastavaa, HV Singhb, A Raizadac, SK Singhd. C-reactive protein, inflammation and coronary heart disease. The Egyptian Heart Journal. 2015;67(2):89-97.

Oikonomou E, Tousoulis D, Siasos G, Zaromitidou M, Papavassiliou AG, Stefanadis C. The role of inflammation in heart failure: new therapeutic approaches. Hellenic J Cardiol. 2011;52(1):30-40.

Westermann D. Does inflammation trigger fibrosis in hypertrophic cardiomyopathy: a burning question? Heart. 2012;98(13):965-6.

Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes. 2007;56(3):641-6.

Klein RM, Vester EG, Brehm MU, Dees H, Picard F, Niederacher D, Beckmann MW, Strauer BE. Inflammation of the myocardium as an arrhythmia trigger. Z Kardiol. 2000;89 Suppl 3:24-35.

Galea J, Armstrong J, Gadsdon P, Holden H, Francis SE, Holt CM. Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 1996;16(8):1000-6.

Ozdemir O, Gundogdu F, Karakelleoglu S, Sevimli S, Pirim I, Acikel M, Arslan S, Serdar S. Comparison of serum levels of inflammatory markers and allelic variant of interleukin-6 in patients with acute coronary syndrome and stable angina pectoris. Coron Artery Dis. 2008;19:15-9.

Commins SP, Borish L, Steinke JW. Immunologic messenger molecules: cytokines, interferons, and chemokines. Allergy Clin Immunol. 2010;125(2 Suppl 2):S53-72.

Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, Tiret L; PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003;108(20):2453-9.

RH Zhou, Q Shi, HQ Gao, BJ Shen. Changes in Serum Interleukin-8 and Interleukin-12 Levels in Patients with Ischemic Heart Disease in a Chinese Population. Journal of Atherosclerosis and Thrombosis. 2001;8:30-32.

Burke SM, Issekutz TB, Mohan K, Lee PW, Shmulevitz M, Marshall JS. Human mas`` cell activation with virus-associated stimuli leads to the selective chemotaxis of natural killer cells by a CXCL8-dependent mechanism. Blood 2008;111:5467-76.

Vaddi K, Nicolini FA, Mehta P, Mehta JL. Increased secretion of tumor necrosis factor-alpha and interferon-gamma by mononuclear leukocytes in patients with ischemic heart disease. Relevance in superoxide anion generation. Circulation. 1994;90(2):694-9.

Eid RE, Rao DA, Zhou J, Lo SF, Ranjbaran H, Gallo A, et al. Interleukin-17 and interferon-gamma are produced concomitantly by human coronary artery-infiltrating T cells and act synergistically on vascular smooth muscle cells. Circulation. 2009;119(10):1424-32.

Abdulkareem MK, Alderzi AR, Saeed BN. Interleukin- 8 and interleukin-10 in patients with ischemic heart disease. The Iraqi Postgraduate Medical Journal. 2013;12:suppl.

Rodriguez AD, Abreu Gonzalez P, Garcia Gonzalez MJ, Ferrer Hita J. Association between serum interleukin 10 level and development of heart failure in acute myocardial infarction patients treated by primary angioplasty. Rev Esp Cardiol. 2005;58(6):626-30.

Nymo SH, Hulthe J, Ueland T, McMurray J, Wikstrand J, Askevold ET, Yndestad A, Gullestad L, Aukrust P. Inflammatory cytokines in chronic heart failure: interleukin-8 is associated with adverse outcome. Results from CORONA. Eur J Heart Fail. 2014;16(1):68-75.

Fairweather D, Frisancho-Kiss S, Yusung SA, Barrett MA, Davis SE, Gatewood SJ, Njoku DB, Rose NR. Interferon-gamma protects against chronic viral myocarditis by reducing mast cell degranulation, fibrosis, and the profibrotic cytokines transforming growth factor-beta 1, interleukin-1 beta, and interleukin-4 in the heart. Am J Pathol. 2004;165(6):1883-94.

Rosello-Lleti E, Rivera M, Bertomeu V, Cortes R, Jordan A, Gonzalez-Molina A. Interleukin-4 and cardiac fibrosis in patients with heart failure. Rev Esp Cardiol. 2007;60(7):777-80.

Y Naito, T Tsujino, Y Fujioka, M Ohyanagi, H Okamura, and T Iwasaki. Increased circulating interleukin- 18 in patients with congestive heart failure. Heart. 2002 Sep; 88(3):296.297.

Vicenova B, Vopalensky V, Burysek L, Pospisek M. Emerging role of interleukin-1 in cardiovascular diseases. Physiol Res. 2009;58(4):481-98.

Van Tassell BW, Toldo S, Mezzaroma E, Abbate A. Targeting interleukin-1 in heart disease. Circulation. 2013;128(17):1910-23.

Mezzaroma E, Mikkelsen RB, Toldo S, Mauro AG, Sharma K, Marchetti C, Alam A, Van Tassell BW, Gewirtz DA, Abbate A. Role of interleukin-1 in radiation induced cardiomyopathy. Mol Med. 2015 Mar 26. doi: 10.2119/molmed.2014.00243. (Epub ahead of print).

Nakamura K, Itoh H, Sagawa N, Kakui K, Nakayama T, Yamada S, Fujii S. A case of peripartum cardiomyopathy with a transient increase of plasma interleukin-6 concentration occurred following mirror syndrome. J Perinat Med. 2002;30(5):426-8.

Hogye M, Mandi Y, Csanady M, Sepp R, Buzas K. Comparison of circulating levels of interleukin-6 and tumor necrosis factor-alpha in hypertrophic cardiomyopathy and in idiopathic dilated cardiomyopathy. Am J Cardiol. 2004;94(2):249-51.

Chen Y, Chen Z, Liao Y, Cao Z, Xia Y, Yang H, Du Y. Effect of tumor necrosis factor-Æ’¿ on ventricular arrhythmias in rats with acute myocardial infarction in vivo. World J Emerg Med. 2010;1(1):53.58.

Vasilets LM, Tuev AV, Agafonov AV, Ratanova EA, Krivaia AA, Trenogina KV, Grigoriadi NE. Ventricular arrhythmias and arterial hypertension: role of inflammatory biomarkers in arrhythmia development. Vestn Ross Akad Med Nauk. 2012;(10):12-7.

Sid EV. Predictor value cytokines for recurrence of arrhythmia in patients with coronary heart disease combined hypertension and persistent atrial fibrillation. Biological Markers and Guided Therapy. 2014;1(2):109-114.

Hadi AR Hadi, Alsheikh-Ali AA, Wael AL Mahmeed, Jassim M Al Suwaidi. Inflammatory cytokines and atrial fibrillation: current and prospective views. J Inflamm Res. 2010;3:75.97.

Pinto A, Tuttolomondo A, Casuccio A. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin Sci (Lond). 2009;116:781-789.

Hak ., My.liwska J, Wieckiewicz J, Szyndler K, Siebert J, Rogowski J. Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG). J Interferon Cytokine Res. 2009;29:327-332.

DOI: http://dx.doi.org/10.14748/ssm.v47i2.1242

Array

Archive 2025 - current

SUBMIT

User Guide